These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23106611)

  • 1. Proteomic and phosphoproteomic analysis of chicken embryo fibroblasts infected with cell culture-attenuated and vaccine strains of Marek's disease virus.
    Chien KY; Blackburn K; Liu HC; Goshe MB
    J Proteome Res; 2012 Dec; 11(12):5663-77. PubMed ID: 23106611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and application of a phosphoproteomic method using electrostatic repulsion-hydrophilic interaction chromatography (ERLIC), IMAC, and LC-MS/MS analysis to study Marek's Disease Virus infection.
    Chien KY; Liu HC; Goshe MB
    J Proteome Res; 2011 Sep; 10(9):4041-53. PubMed ID: 21736374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mass spectrometry-based proteomic approach to study Marek's Disease Virus gene expression.
    Liu HC; Soderblom EJ; Goshe MB
    J Virol Methods; 2006 Jul; 135(1):66-75. PubMed ID: 16563527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased virulence of Marek's disease virus type 1 vaccine strain CV1988 after adaptation to qt35 cells.
    Majerciak V; Valkova A; Szabová D; Geerligs H; Zelník V
    Acta Virol; 2001 Apr; 45(2):101-8. PubMed ID: 11719980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of four very virulent Argentinian strains of Marek's disease virus and the influence of one of those isolates on synergism between Marek's disease vaccine viruses.
    Buscaglia C; Nervi P; Risso M
    Avian Pathol; 2004 Apr; 33(2):190-5. PubMed ID: 15276986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the Gallus gallus proteome induced by Marek's disease virus.
    Ramaroson MF; Ruby J; Goshe MB; Liu HC
    J Proteome Res; 2008 Oct; 7(10):4346-58. PubMed ID: 18712901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of Marek's disease virus (MDV) glycoprotein-, lytic antigen pp38- and transformation antigen Meq-encoding genes: association of meq mutations with MDVs of high virulence.
    Shamblin CE; Greene N; Arumugaswami V; Dienglewicz RL; Parcells MS
    Vet Microbiol; 2004 Sep; 102(3-4):147-67. PubMed ID: 15327791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial inhibition by turkey herpesvirus of serotype 2 Marek's disease virus plaque formation and in vivo infectivity.
    Witter RL; Bacon LD; Calvert JG
    Avian Dis; 1994; 38(4):800-9. PubMed ID: 7702514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early posthatch protection against Marek's disease in chickens vaccinated in ovo with a CVI988 serotype 1 vaccine.
    Zhang Y; Sharma JM
    Avian Dis; 2001; 45(3):639-45. PubMed ID: 11569737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: comparative efficacy.
    Witter RL
    Avian Dis; 1987; 31(4):752-65. PubMed ID: 2831867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: selected biological and molecular characteristics.
    Witter RL; Silva RF; Lee LF
    Avian Dis; 1987; 31(4):829-40. PubMed ID: 2831870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a cell line system susceptible to infection with vaccine strains of MDV.
    Abujoub AA; Williams DL; Reilly JD
    Acta Virol; 1999; 43(2-3):186-91. PubMed ID: 10696443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988.
    Ajithdoss DK; Reddy SM; Suchodolski PF; Lee LF; Kung HJ; Lupiani B
    Virus Res; 2009 Jun; 142(1-2):57-67. PubMed ID: 19189855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens.
    Geerligs H; Quanz S; Suurland B; Spijkers IE; Rodenberg J; Davelaar FG; Jongsma B; Kumar M
    Vaccine; 2008 Oct; 26(44):5595-600. PubMed ID: 18706949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses.
    Gimeno IM; Dunn JR; Cortes AL; El-Gohary Ael-G; Silva RF
    Avian Dis; 2014 Jun; 58(2):232-43. PubMed ID: 25055627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological characteristics of a membrane glycoprotein gp82 of Marek's disease virus.
    Wu P; Lee LF; Reed WM
    Avian Dis; 1997; 41(4):824-31. PubMed ID: 9454915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine responses and inducible nitrous oxide synthase expression patterns in neonatal chicken brain microglia infected with very virulent Marek's disease virus strain YL040920.
    Yang Q; Wei P; Chen H
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):14-24. PubMed ID: 21501879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative full-length sequence analysis of Marek's disease virus vaccine strain 814.
    Zhang F; Liu CJ; Zhang YP; Li ZJ; Liu AL; Yan FH; Cong F; Cheng Y
    Arch Virol; 2012 Jan; 157(1):177-83. PubMed ID: 21984218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of the vaccinating properties of 2 variants of Marek's disease virus].
    Iakovleva LS; Merekalova ZI; Pavlovskaia AI; Plakhov IV; Mazurenko NP
    Vopr Virusol; 1977; (4):493-6. PubMed ID: 200016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains.
    de Boer GF; Groenendal JE; Boerrigter HM; Kok GL; Pol JM
    Avian Dis; 1986; 30(2):276-83. PubMed ID: 3015113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.